The proteomics of cancer stem cells. Potential clinical applications for innovative research in oncology

Proteomics - Clinical Applications

Volumn 5, Issue 11-12, 2011, Pages 590-602

  Scatena, Roberto ^a   Bottoni, Patrizia ^a   Pontoglio, Alessandro ^a   Giardina, Bruno ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Cancer biomarker; Cancer stem cell; Oncoproteomics; Stem cell; Tumour circulating cell

Indexed keywords

CELL SURFACE MARKER; TUMOR MARKER;

APOPTOSIS; CANCER RESEARCH; CANCER STEM CELL; CELL DEDIFFERENTIATION; CELL DIFFERENTIATION; CELL RENEWAL; DOWN REGULATION; EPIGENETICS; GENE OVEREXPRESSION; HUMAN; MASS SPECTROMETRY; NONHUMAN; ONCOGENE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CONTENT; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN MICROARRAY; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEOMICS; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; TUMOR MICROENVIRONMENT; TUMOR SUPPRESSOR GENE; UPREGULATION;

ANIMALS; CELL LINE, TUMOR; HUMANS; NEOPLASMS; NEOPLASTIC STEM CELLS; PROTEOMICS;

EID: 84855174885     PISSN: 18628346     EISSN: 18628354     Source Type: Journal    
DOI: 10.1002/prca.201000142     Document Type: Review

References (90)

1. Clarke, M. F., Dick, J. E., Dirks, P. B., Eaves, C. J. et al., Cancer stem cells-perspectives on current status and future directions: AACR workshop on cancer stem cells. Cancer Res. 2006, 66, 9339-9344.
2. Shackleton, M., Normal stem cells and cancer stem cells: similar and different. Semin. Cancer Biol. 2010, 20, 85-92.
3. Stricker, T. P., Kumar, V., in: Kumar, V., Abbas, A. K., Fausto, N., Aster, J. C. (Eds.), Robbins and Cotran Pathologic Basis of Disease, Elsevier Saunders, Philadelphia 2010, pp. 259-330.
4. Visvader, J. E., Cells of origin in cancer. Nature 2011, 469, 314-322.
5. Wang, J. C. Y., Dick, J. E. in: De Vita, V. T., Lawrence, T. S., Rosenberg, S. A. (Eds.), Cancer: Principles & Practice of Oncology. Lippincott Williams & Wilkins, Philadelphia 2008, pp. 135-143.
6. Pierce, G. B., Speers, W. C., Tumors as caricatures of the process of tissue renewal: prospects for therapy by directing differentiation. Cancer Res. 1988, 48, 1996-2004.
7. Bonnet, D., Dick, J. E., Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997, 3, 730-737.
8. Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J., Clarke, M. F., Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. USA 2003, 100, 3983-3988.
9. Quintana, E., Shackleton, M., Sabel, M. S., Fullen, D. R. et al., Efficient tumour formation by single human melanoma cells. Nature 2008, 456, 593-598.
10. O'Brien, C. A., Pollett, A., Gallinger, S., Dick, J. E., A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007, 445, 106-110.
11. Collins, A. T., Berry, P. A., Hyde, C., Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 2005, 65, 10946-10951.
12. Sell, S., Leffert, H. L., Liver cancer stem cells. J. Clin. Oncol. 2008, 26, 2800-2805.
13. Li, C., Heidt, D. G., Dalerba, P., Burant, C. F. et al., Identification of pancreatic cancer stem cells. Cancer Res. 2007, 67, 1030-1037.
14. Singh, S. K., Clarke, I. D., Terasaki, M., Bonn, V. E. et al., Identification of a cancer stem cell in human brain tumors. Cancer Res. 2003, 63, 5821-5828.
15. Florian, S., Sonneck, K., Hauswirth, A. W., Krauth, M. T. et al., Detection of molecular targets on the surface of CD34+/CD38 - stem cells in various myeloid malignancies. Leuk. Lymphoma 2006, 47, 207-222.
16. Reya, T., Morrison, S. J., Clarke, M. F., Weissman, I. L., Stem cells, cancer, and cancer stem cells. Nature 2001, 414, 105-111.
17. Visvader, J. E., Lindeman, G. J., Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat. Rev. Cancer 2008, 8, 755-768.
18. Taussig, D. C., Miraki-Moud, F., Anjos-Afonso, F., Pearce, D. J. et al., Anti-CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells. Blood 2008, 112, 568-575.
19. Clevers, H., The cancer stem cell: premises, promises and challenges. Nat. Med. 2011, 17, 313-319.
20. Gupta, P. B., Chaffer, C. L., Weinberg, R. A., Cancer stem cells: mirage or reality? Nat. Med. 2009, 15, 1010-1012.
21. Maenhaut, C., Dumont, J. E., Roger, P. P., van Staveren, W. C. G., Cancer stem cells: a reality, a myth, a fuzzy concept or a misnomer? An analysis. Carcinogenesis 2010, 31, 149-158.
22. Schatton, T., Murphy, G. F., Frank, N. Y., Yamaura, K. et al., Identification of cells initiating human melanomas. Nature 2008, 451, 345-349.
23. Dean, M., Fojo, T., Bates, S., Tumour stem cells and drug resistance. Nat. Rev. Cancer 2005, 5, 275-284.
24. Amariglio, N., Hirshberg, A., Scheithauer, B. W., Cohen, Y. et al., Donor-derived brain tumor following neural stem cell transplantation in an ataxia telangiectasia patient. PLoS Med. 2009, 6:e1000029.
25. Scatena, R., Bottoni, P., Pontoglio, A., Giardina, B., Cancer stem cells: the development of new cancer therapeutics. Exp. Opin. Biol. Ther. 2011, 11, 875-892.
26. Dalerba, P., Cho, R. W., Clarke, M. F., Cancer stem cells: models and concepts. Annu. Rev. Med. 2007, 58, 267-284.
27. Lottaz, C., Beier, D., Meyer, K., Kumar, P. et al., Transcriptional profiles of CD133+and CD133- glioblastoma-derived cancer stem cell lines suggest different cells of origin. Cancer Res. 2010, 70, 2030-2040.
28. Beck, H. C., Nielsen, E. C., Matthiesen, R., Jensen, L. H. et al., Quantitative proteomic analysis of post-translational modifications of human histones. Mol. Cell. Proteomics 2006, 5, 1314-1325.
29. Foss, E. J., Radulovic, D., Shaffer, S. A., Ruderfer, D. M. et al., Genetic basis of proteome variation in yeast. Nat. Genet. 2007, 39, 1369-1375.
30. Scatena, R., Bottoni, P., Giardina, B., Modulation of cancer cell line differentiation: a neglected proteomic analysis with potential implications in pathophysiology, diagnosis, prognosis, and therapy of cancer. Proteomics Clin. Appl. 2008, 2, 229-237.
31. Kondo, T., Stem cell-like cancer cells in cancer cell lines. Cancer Biomarkers 2007, 3, 245-250.
32. Navakauskiene, R., Treigyte, G., Gineitis, A., Magnusson, K. E., Identification of apoptotic tyrosine-phosphorylated proteins after etoposide or retinoic acid treatment. Proteomics 2004, 4, 1029-1041.
33. Bottoni, P., Giardina, B., Vitali, A., Boninsegna, A., Scatena, R., A proteomic approach to characterizing ciglitazone-induced cancer cell differentiation in Hep-G2 cell line. Biochim. Biophys. Acta. 2009, 1794, 615-626.
34. Warrel, R. P., in: De Vita, V. T., Hellmann, S., Rosenberg, S. A. (Eds.), Cancer: Principles and Practice of Oncology, J. B. Lippincott Company, Philadelphia 2001, pp. 489-494.
35. Calleja, E. M., Warrell, R. P., Jr., Differentiating agents in pediatric malignancies: All-trans-retinoic acid and arsenic in acute promyelocytic leukemia. Curr. Oncol. Rep. 2000, 2, 519-523.
36. Qumsiyeh, M. B., Li, P., in: De Vita, V. T., Hellmann, S., Rosenberg, S. A. (Eds.), Cancer: Principles and Practice of Oncology, J. B. Lippincott Company, Philadelphia 2001, pp. 77-90.
37. Alison, M. R., Lim, S. M., Nicholson, L. J., Cancer stem cells: problems for therapy? J. Pathol. 2011, 223, 147-161.
38. Ma, S., Chan, K. W., Lee, T. K., Tang, K. H. et al., Aldehyde dehydrogenase discriminates the CD133 liver cancer stem cell populations. Mol. Cancer Res. 2008, 6, 1146-1153.
39. Ginestier, C., Hur, M. H., Charafe-Jauffret, E., Monville, F. et al., ALDH1 is a marker of normal and malignant human mammary stem cells and predictor of poor clinical outcome. Cell Stem Cell 2007, 1, 555-567.
40. Cheung, A. M., Wan, T. S., Leung, J. C., Chan, L. Y. et al., Aldehyde dehydrogenase activity in leukemic blasts defines a subgroup of acute myeloid leukemia with adverse prognosis and superior NOD/SCID engrafting potential. Leukemia 2007, 21, 1423-1430.
41. Chen, Y. C., Chen, Y. W., Hsu, H. S., Tseng, L. M. et al., Aldehyde dehydrogenase 1 is a putative marker for cancer stem cells in head and neck squamous cancer. Biochem. Biophys. Res. Commun. 2009, 385, 307-313.
42. Li, T., Su, Y., Mei, Y., Leng, Q. et al., ALDH1A1 is a marker for malignant prostate stem cells and predictor of prostate cancer patients' outcome. Lab. Invest. 2010, 90, 234-244.
43. Rasheed, Z. A., Yang, J., Wang, Q., Kowalski, J. et al., Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma. J. Natl. Cancer Inst. 2010, 102, 340-351.
44. Chen, R., Nishimura, M. C., Bumbaca, S. M., Kharbanda, S. et al., A hierarchy of self-renewing tumor-initiating cell types in glioblastoma. Cancer Cell 2010, 17, 362-375.
45. Lugli, A., Iezzi, G., Hostettler, I., Muraro, M. G. et al., Prognostic impact of the expression of putative cancer stem cell markers CD133, CD166, CD44s, EpCAM, and ALDH1 in colorectal cancer. Br. J. Cancer 2010, 103, 382-390.
46. Lee, E. K., Han, G. Y., Park, H. W., Song, Y. J., Kim, C. W., Transgelin promotes migration and invasion of cancer stem cells. J. Proteome Res. 2010, 9, 5108-5117.
47. Muller, A., Homey, B., Soto, H., Ge, N. et al., Involvement of chemokine receptors in breast cancer metastasis. Nature 2001, 410, 50-56.
48. Fang, D. D., Kim, Y. J., Lee, C. N., Aggarwal, S. et al., Expansion of CD133(+) colon cancer cultures retaining stem cell properties to enable cancer stem cell target discovery. Br. J. Cancer 2010, 102, 1265-1275.
49. Goodell, M. A., Brose, K., Paradis, G., Conner, A. S., Mulligan, R. C., Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J. Exp. Med. 1996, 183, 1797-1806.
50. Hadnagy, A., Gaboury, L., Beaulieu, R., Balicki, D., SP analysis may be used to identify cancer stem cell populations. Exp Cell Res 2006, 312, 3701-3710.
51. Wu, C., Alman, B. A., Side population cells in human cancers. Cancer Lett. 2008, 268, 1-9.
52. Steiniger, S. C., Coppinger, J. A., Krüger, J. A., Yates, J., 3rd, Janda, K. D., Quantitative mass spectrometry identifies drug targets in cancer stem cell-containing side population. Stem Cells 2008, 26, 3037-3046.
53. Ricci-Vitiani, L., Collinari, C., di Martino, S., Biffoni, M. et al., Thymosin beta4 targeting impairs tumorigenic activity of colon cancer stem cells. FASEB J. 2010, 24, 4291-4301.
54. Scatena, R., Bottoni, P., Pontoglio, A., Giardina, B., Revisiting the Warburg effect in cancer cells with proteomics. The emergence of new approaches to diagnosis, prognosis and therapy. Proteomics Clin. Appl. 2010, 4, 143-158.
55. Christofk, H. R., Vander Heiden, M. G., Wu, N., Asara, J. M., Cantley, L. C., Pyruvate kinase M2 is a phosphotyrosinebinding protein. Nature 2008, 452, 181-186.
56. Scatena, R., Bottoni, P., Pontoglio, A., Mastrototaro, L., Giardina, B., Glycolytic enzyme inhibitors in cancer treatment. Exp. Opin. Invest. Drugs 2008, 17, 1533-1545.
57. Dormeyer, W., van Hoof, D., Braam, S. R., Heck, A. J. et al., Plasma membrane proteomics of human embryonic stem cells and human embryonal carcinoma cells. J. Proteome Res. 2008, 7, 2936-2951.
58. Seliger, B., Molecular mechanisms of MHC class I abnormalities and APM components in human tumors. Cancer Immunol. Immunother. 2008, 57, 1719-1726.
59. Chaerkady, R., Kerr, C. L., Kandasamy, K., Marimuthu, A. et al., Comparative proteomics of human embryonic stem cells and embryonal carcinoma cells. Proteomics 2010, 10, 1359-1373.
60. Nilsson, C. L., Dillon, R., Devakumar, A., Shi, S. D. et al., Quantitative phosphoproteomic analysis of the STAT3/IL-6/HIF1alpha signalling network: an initial study in GSC11 glioblastoma stem cells. J. Proteome Res. 2010, 9, 430-443.
61. Levy, D. E., Darnell, J. E., Jr., Stats: Transcriptional control and biological impact. Nat. Rev. Mol. Cell. Biol. 2002, 3, 651-662.
62. Leslie, K., Lang, C., Devgan, G., Azare, J. et al., Cyclin D1 is transcriptionally regulated by and required for transformation by activated signal transducer and activator of transcription 3. Cancer Res. 2006, 66, 2544-2552.
63. Bromberg, J., Stat proteins and oncogenesis. J. Clin. Invest. 2002, 109, 1139-1142.
64. Sherry, M. M., Reeves, A., Wu, J. K., Cochran, B. H., STAT3 is required for proliferation and maintenance of multipotency in glioblastoma stem cells. Stem Cells 2009, 27, 2383-2392.
65. Heimberger, A. B., Priebe, W., Small molecular inhibitors of p-STAT3: novel agents for treatment of primary and metastatic CNS cancers. Recent Pat. CNS Drug Discov. 2008, 3, 179-188.
66. Villalva, C., Martin-Lannerée, S., Cortes, U., Dkhissi, F. et al., STAT3 is essential for the maintenance of neurosphere-initiating tumor cells in patients with glioblastomas: a potential for targeted therapy? Int. J. Cancer 2011, 128, 826-838.
67. Vaupel, P., The role of hypoxia-induced factors in tumor progression. Oncologist 2004, 9, 10-17.
68. Beachy, P. A., Karhadkar, S. S., Berman, D. M., Tissue repair and stem cell renewal in carcinogenesis. Nature 2004, 432, 324-331.
69. Natarajan, T. G., FitzGerald, K. T., Markers in normal and cancer stem cells. Cancer Biomarkers 2007, 3, 211-231.
70. Madoz-Gurpide, J., Canamero, M., Sanchez, L., Solano, J. et al., A proteomics analysis of cell signaling alterations in colorectal cancer. Mol. Cell. Proteomics 2007, 6, 2150-2164.
71. Mahmoudi, T., Li, V. S., Ng, S. S., Taouatas, N. et al., The kinase TNIK is an essential activator of Wnt target genes. EMBO J. 2009, 28, 3329-3340.
72. Lee, W. J., Kim, D. U., Lee, M. Y., Choi, K. Y., Identification of proteins interacting with the catalytic subunit of PP2A by proteomics. Proteomics 2007, 7, 206-214.
73. Wei, G., Ku, S., Ma, G. K., Saito, S. et al., HIPK2 represses beta-cateninmediated transcription, epidermal stem cell expansion, and skin tumorigenesis. Proc. Natl. Acad. Sci. USA 2007, 104, 13040-13045.
74. Huang, S. M., Mishina, Y. M., Liu, S., Cheung, A. et al., Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature 2009, 461, 614-620.
75. Brennan, C., Momota, H., Hambardzumyan, D., Ozawa, T. et al., Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations. PLoS One 2009, 4, e7752.
76. Wang, Z., Li, Y., Banerjee, S., Sarkar, F. H., Emerging role of Notch in stem cells and cancer. Cancer Lett. 2009, 279, 8-12.
77. Woodward, W. A., Chen, M. S., Behbod, F., Alfaro, M. P. et al., WNT/beta-catenin mediates radiation resistance of mouse mammary progenitor cells. Proc. Natl. Acad. Sci. USA 2007, 104, 618-623.
78. Wang, J., Wakeman, T. P., Lathia, J. D., Hjelmeland, A. B. et al., Notch promotes radioresistance of glioma stem cells. Stem Cells 2010, 28, 17-28.
79. Baumann, M., Krause, M., Hill, R., Exploring the role of cancer stem cells in radioresistance. Nat. Rev. Cancer 2008, 8, 545-554.
80. Zhou, C., Nitschke, A. M., Xiong, W., Zhang, Q. et al., Proteomic analysis of tumor necrosis factor-alpha resistant human breast cancer cells reveals a MEK5/Erk5-mediated epithelial-mesenchymal transition phenotype. Breast Cancer Res. 2008, 10, R105.
81. Skvortsova, I., Skvortsov, S., Stasyk, T., Raju, U. et al., Intracellular signaling pathways regulating radioresistance of human prostate carcinoma cells. Proteomics 2008, 8, 4521-4533.
82. Keenan, J., Murphy, L., Henry, M., Meleady, P., Clynes, M., Proteomic analysis of multidrug-resistance mechanisms in adriamycin-resistant variants of DLKP, a squamous lung cancer cell line. Proteomics 2009, 9, 1556-1566.
83. Lee, D. H., Chung, K., Song, J. A., Kim, T. H. et al., Proteomic identification of paclitaxel-resistance associated hnRNP A2 and GDI 2 proteins in human ovarian cancer cells. J. Proteome Res. 2010, 9, 5668-5676.
84. Dai, Z., Yin, J., He, H., Li, W. et al., Mitochondrial comparative proteomics of human ovarian cancer cells and their platinum-resistant sublines. Proteomics 2010, 10, 3789-3799.
85. Renner, K., Amberger, A., Konwalinka, G., Kofler, R., Gnaiger, E., Changes of mitochondrial respiration, mitochondrial content and cell size after induction of apoptosis in leukemia cells. Biochim. Biophys. Acta 2003, 1642, 115-123.
86. Scatena, R., Bottoni, P., Botta, G., Martorana, G. E., Giardina, B., The role of mitochondria in pharmacotoxicology: a reevaluation of an old, newly emerging topic. Am. J. Physiol. Cell. Physiol. 2007, 293, C12-C21.
87. Wiederschain, D., Chen, L., Johnson, B., Bettano, K. et al., Contribution of polycomb homologues Bmi-1 and Mel-18 to medulloblastoma pathogenesis. Mol. Cell. Biol. 2007, 27, 4968-4979.
88. Chung, J. Y., Hong, S. M., Choi, B. Y., Cho, H. et al., The expression of phospho-AKT, phospho-mTOR, and PTEN in extrahepatic cholangiocarcinoma. Clin. Cancer Res. 2009, 15, 660-667.
89. Ahn, Y., Hwang, C. Y., Lee, S. R., Kwon, K. S., Lee, C., The tumour suppressor PTEN mediates a negative regulation of the E3 ubiquitin-protein ligase Nedd4. Biochem. J. 2008, 412, 331-338.
90. Stemke-Hale, K., Gonzalez-Angulo, A. M., Lluch, A., Neve, R. M. et al., An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res. 2008, 68, 6084-6091.